Kim S. Erlich, MD; Mark A. Jacobson, MD; Jane E. Koehler, MD; Stephen E. Follansbee, MD; David P. Drennan, MD; Lisa Gooze, MD; Sharon Safrin, MD; John Mills, MD
Study Objective: To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS).
Design: Open-labeled drug administration to patients with AIDS and severe ulcerative disease due to acyclovir-resistant HSV-2 infection.
Setting: Medical floors of acute care hospital.
Patients: Four patients with AIDS who developed progressive ulcerative mucocutaneous lesions of the genitals, perineum, perianal region, or finger due to acyclovir-resistant, thymidine-kinase (TK)-negative strains of HSV-2.
Intervention: Foscarnet, 60 mg/kg body weight intravenously every 8 hours (with reduced dosage for renal impairment), for 12 to 50 days.
Measurement and Main Results: All patients receiving foscarnet had dramatic improvement in their clinical findings with marked clearing of mucocutaneous lesions and eradication of HSV from mucosal surfaces.
Conclusion: Foscarnet may be an effective treatment for severe mucocutaneous disease due to acyclovir-resistant, TK-negative strains of HSV-2.
Erlich KS, Jacobson MA, Koehler JE, et al. Foscarnet Therapy for Severe Acyclovir-Resistant Herpes Simplex Virus Type-2 Infections in Patients with the Acquired Immunodeficiency Syndrome (AIDS): An Uncontrolled Trial. Ann Intern Med. 1989;110:710–713. doi: https://doi.org/10.7326/0003-4819-110-9-710
Download citation file:
Published: Ann Intern Med. 1989;110(9):710-713.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use